Inc Research Holdings, Inc. (INCR): Christopher L Gaenzle , CAO, GC & Sec of Inc Research Holdings, Inc. sold 21,918 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were sold at $40.21 per share for a total value of $881,076.56 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, Robert W Breckon (director) sold 421 shares at $37.97 per share price.On Jul 5, 2016, Gregory S Rush (Executive VP and CFO) sold 1,358 shares at $37.97 per share price.Also, On Jun 16, 2016, Christopher L Gaenzle (CAO, GC & Sec) sold 7,702 shares at $40.13 per share price.On Jun 7, 2016, Michael Gibertini (President Clinical Development) sold 213,966 shares at $43.45 per share price.
INC Research Holdings Inc: On Monday, Jul 11, 2016 heightened volatility was witnessed in INC Research Holdings Inc which led to swings in the share price. The shares opened for trading at $39.88 and hit $40.41 on the upside , eventually ending the session at $40.27, with a gain of 1.77% or 0.7 points. The heightened volatility saw the trading volume jump to 5,05,170 shares. The 52-week high of the share price is $57.11 and the company has a market cap of $2,184 M . The 52-week low of the share price is at $34.19.
Company has been under the radar of several Street Analysts.INC Research Holdings Inc is Initiated by Credit Suisse to Outperform and the brokerage firm has set the Price Target at $51. The Rating was issued on Jun 21, 2016.INC Research Holdings Inc is Downgraded by Robert W. Baird to Neutral while Lowering the Price Target of the company shares to $ 51 from a previous price target of $55 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on May 3, 2016.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.